Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT-02 add-on in mesalamine-refractory ulcerative colitis
NCT02849951Phase 3Terminated
- Sponsor
- Prometheus Laboratories
- Start
- Jul 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ulcerative colitis (UC) comparing LT-02 with Placebo (2 arms). Primary endpoint: Rate of clinical remission at 12 weeks. Started Jul 2016; status: terminated.
02
Drugs
phosphatidylcholine (LT-02)
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02849951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02849951.